ArticleProceedings (Baylor University. Medical Center)2024
The Egyptian journey from having the highest prevalence of hepatitis C virus to being the first to achieve "gold tier" in conquering the disease.
Article in Proceedings (Baylor University. Medical Center), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06942962 (Assessment of Lymphocyte Subset Functions in Children Admitted to Assiut University Children Hospital With Acute Hepatitis A Infection), which is not on this map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Assessment of Lymphocyte Subset Functions in Children Admitted to Assiut University Children Hospital With Acute Hepatitis A Infection
Who cites it
5 citing papers in PubMed.
- Challenges and achievements on the road to hepatitis elimination.Nature communications · 2026Article
- From endorsement of the WHO Acceleration Plan to Stop Obesity to national implementation: country progress on health system preparedness to scale up a comprehensive obesity chronic care programme.The Lancet. Global health · 2026Review
- Gut microbiome dysbiosis in hepatocellular carcinoma patients with persistent HCV viremia versus viral clearance: a cross-sectional study.Gut pathogens · 2025Article
- Perceptions about hepatitis C and barriers and enablers to screening and treatment among Egyptian immigrants to Canada: a theory-informed qualitative study.International journal for equity in health · 2025Article
- Epidermal Growth Factor (EGF rs4444903) Gene Polymorphism and Risk of HCC in Egyptian HCV Cirrhotic Patients.Asian Pacific journal of cancer prevention : APJCP · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis C virus (HCV) is a major global health concern, particularly in Egypt, due to historic schistosomiasis control efforts that inadvertently led to widespread HCV transmission. This study aimed to evaluate the efficacy of Egypt's national strategies in controlling and reducing the prevalence of HCV, including introducing sofosbuvir and implementing the "100 Million Healthy Lives" campaign. The approach includes a review of epidemiological data, an analysis of the national HCV control strategies implemented, and an assessment of their outcomes, focusing on the period from 2006 to 2022. Significant milestones were achieved, including a drastic reduction in new HCV infections from 300 per 100,000 in 2014 to 9 per 100,000 in 2022 and successful treatment of over 4 million people. Egypt has become the first country in the world to achieve the "gold tier" status based on World Health Organization criteria on the path to eradication of HCV. Egypt's comprehensive approach can serve as a model for similar endemic regions. Other nations with high HCV prevalence might benefit from adopting similar multidimensional strategies, emphasizing prevention and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.